Revolution Medicines, Inc. RVMD

NASDAQ | Biotech | Oncology / RAS-targeted therapies

General analysis — not personal advice.

Signal

BUY

Sentiment

9/10

Risk

6/10

The Phase 3 outcome with a large OS benefit and manageable safety meaningfully reduces clinical/regulatory uncertainty and increases the probability of approval and commercialization.

This picture changes. Follow Revolution Medicines, Inc. free — email when the signal or risk changes + a Sunday weekly brief.

Follow Revolution Medicines, Inc. free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Price & valuation

Last close

USD 207

2026-08-10

1 week

+4.9 %

3 months

+38.0 %

Market sentiment

Sentiment has turned strongly positive post ASCO/NEJM with broad media coverage and investor discussions framing the data as potentially practice-changing; attention is now on regulatory path and launch readiness.

Why BUY?

The Phase 3 outcome with a large OS benefit and manageable safety meaningfully reduces clinical/regulatory uncertainty and increases the probability of approval and commercialization. Key risks remain around execution (regulatory timing, scale-up, pricing/reimbursement) and a high cost base, but the post-April financing cash balance reduces near-term funding risk.

ADD: Consider scaling in (e.g., tranches) ahead of regulatory filing/updates, while maintaining risk controls given potential volatility around agency interactions and launch specifics.

We're already tracking Revolution Medicines, Inc. — here are the latest events we've registered

Recent News

Revolution Medicines reported Phase 3 (RASolute 302) daraxonrasib results in metastatic RAS-mutant pancreatic cancer at ASCO with concurrent publication (NEJM), showing median OS 13.2 vs ~6.6–6.7 months (HR 0.40) plus improved PFS and response rate. FDA also issued a “safe to proceed” letter for an expanded access program, and the company outlined accelerated global regulatory filings and commercial build-out.

Catalysts

Global regulatory filings for daraxonrasib

Dilution Risk

Assessment: Low

Create free account — follow 3 companies

What Firelda Watch includes for Revolution Medicines, Inc.

Add the company to your watchlist and get all of this automatically.

Free: 3 companies on your watchlist
Change history and monitoring for every company you follow
Sunday weekly brief — AI roundup of the week's news
Watch/Ultra: same-day email when something material happens

Want to see what a finished analysis looks like?

View a sample analysis

This is a real Firelda analysis. Your analysis of Revolution Medicines, Inc. will be delivered in the same format.

Own Revolution Medicines, Inc.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free